JNJ Shariah Compliance
Screening Methodology: AAOIFI
HALAL
Last Updated: May 01, 2026
Report Source: 2026 1st Quarter Report
Johnson & Johnson. Stock Analysis JNJ
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. The company is headquartered in New Brunswick, New Jersey and currently employs 138,100 full-time employees. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
Read More Johnson & Johnson (JNJ) Chart
Key Statistics of Johnson & Johnson (JNJ)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$225.51Volume
8.22MP/E Ratio (TTM)
20.4152 Week Range
Market Cap
547.51BAvg. Volume
7.61MDividend Yield
2.26%Financial Metrics & Statements of Johnson & Johnson (JNJ)
FAQ's for Johnson & Johnson (JNJ)
- According to Musaffa’s Shariah screening methodology, Johnson & Johnson (JNJ) is currently classified as HALAL as of May 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.